Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | STS | P08842 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6026752 | 1.00 | CHRM2 (0.39) | CHRM2CHRM1CHRM3EPHX1HPGD | |
| SCHEMBL6026756 | 1.00 | CHRM2 (0.39) | CHRM2CHRM1CHRM3EPHX1HPGD | |
| SCHEMBL13125666 | 1.00 | CHRM2 (0.39) | CHRM2CHRM1CHRM3EPHX1HPGD | |
| SCHEMBL4370463 | 1.00 | CHRM2 (0.39) | CHRM2CHRM1CHRM3EPHX1HPGD | |
| SCHEMBL28044757 | 0.85 | EPHX1 (0.37) | CHRM2CHRM1CHRM3EPHX1HPGD | |
| SCHEMBL28735688 | 0.85 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1HPGD | |
| SCHEMBL29519744 | 0.85 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1HPGD | |
| SCHEMBL25348441 | 0.85 | ALDH1A1 (0.38) | CHRM2CHRM1CHRM3EPHX1HPGD | |
| SCHEMBL30782513 | 0.85 | ALDH1A1 (0.38) | CHRM2CHRM1CHRM3EPHX1HPGD | |
| SCHEMBL24069211 | 0.80 | CHRM2 (0.44) | CHRM2CHRM1CHRM3EPHX1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989640-B2 | Sulfonylpyrrolidine modulators of androgen receptor function and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989640-B2 | Sulfonylpyrrolidine modulators of androgen receptor function and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989640-B2 | Sulfonylpyrrolidine modulators of androgen receptor function and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110015408-A1 | SULFONYLPYRROLIDINE MODULATORS OF ANDROGEN RECEPTOR FUNCTION AND METHOD | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-20 | — | — | US | disclosed |
| US-20110015408-A1 | SULFONYLPYRROLIDINE MODULATORS OF ANDROGEN RECEPTOR FUNCTION AND METHOD | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-20 | — | — | US | disclosed |
| US-20110015408-A1 | SULFONYLPYRROLIDINE MODULATORS OF ANDROGEN RECEPTOR FUNCTION AND METHOD | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-20 | — | — | US | disclosed |
| US-7820702-B2 | Nonsteroidal, nontoxic tissue selective modulators for side effect reduction; age-related and androgen-receptor related conditions such as sarcopenia; e.g. 4-(4-Hydroxy-1,1,3-trioxohexahydrothia-2,6a-diazapentalen-2-yl)-2-chloro-3-methylbenzonitrile | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820702-B2 | Nonsteroidal, nontoxic tissue selective modulators for side effect reduction; age-related and androgen-receptor related conditions such as sarcopenia; e.g. 4-(4-Hydroxy-1,1,3-trioxohexahydrothia-2,6a-diazapentalen-2-yl)-2-chloro-3-methylbenzonitrile | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-26 | — | — | US | disclosed |
| US-7772267-B2 | or other nuclear hormone receptors inhibitors; 4-(7-Hydroxy-1,3-dioxo-tetrahydropyrrolo[1,2-c]imidazol-2-yl)-5,6,7,8-tetrahydronaphthalene-1-carbonitrile; age-related diseases: sarcopenia, muscular atrophy, lipodistrophy, long-term critical illness, chronic fatigue syndrome, bone fracture repair | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772267-B2 | or other nuclear hormone receptors inhibitors; 4-(7-Hydroxy-1,3-dioxo-tetrahydropyrrolo[1,2-c]imidazol-2-yl)-5,6,7,8-tetrahydronaphthalene-1-carbonitrile; age-related diseases: sarcopenia, muscular atrophy, lipodistrophy, long-term critical illness, chronic fatigue syndrome, bone fracture repair | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| US-7405234-B2 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| US-20080108649-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080108649-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| EP-1506178-A4 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20060100199-A1 | Novel condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-20050187267-A1 | Sulfonylpyrrolidine modulators of androgen receptor function and method | BRISTOL-MYERS SQUIBB COMPANY | 2005-08-25 | — | — | US | disclosed |
| EP-1506178-A2 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | Bristol-Myers Squibb Company (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20040181064-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-16 | — | — | US | disclosed |
| US-20040019063-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-29 | — | — | US | disclosed |
| WO-2003096980-A2 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019063-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | CHRM2 533/4885CHRM1 537/4885CHRM3 480/4885 |
| US-20050187267-A1 | Sulfonylpyrrolidine modulators of androgen receptor function and method | NR3C2, AR, NR4A3 | CHRM2 138/4885CHRM1 206/4885CHRM3 87/4885 |
| US-20040181064-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | CHRM2 489/4885CHRM1 461/4885CHRM3 423/4885 |
| US-20080108649-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | AR, ESRRA, SHBG | CHRM2 467/4885CHRM1 536/4885CHRM3 352/4885 |
| US-20060100199-A1 | Novel condensed imidazole derivatives | H1-2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-4 | CHRM2 44/4885CHRM1 19/4885CHRM3 175/4885 |
| US-20110015408-A1 | SULFONYLPYRROLIDINE MODULATORS OF ANDROGEN RECEPTOR FUNCTION AND METHOD | AR, NR5A1, NR4A1 | CHRM2 685/4885CHRM1 672/4885CHRM3 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.